Business
ASX 200 on watch after study shows Moderna’s COVID-19 vaccine is 94.5% effective // Motley Fool Australia
The S&P/ASX 200 Index (ASX: XJO) could be given a boost today from news that there is now a second potentially effective COVID-19 vaccine.
Overnight, biotechnology company Moderna released an update on its Phase 3 study of mRNA-1273.
What did Moderna announce?
According to the release, the National Institutes of Health-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%.
This study enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID).
The primary endpoint of the…
-
Noosa News14 hours agoFormer NRL player Teui ‘TC’ Robati lured woman to pub toilet before alleged rape, jury told
-
Noosa News22 hours agoCattle claimants ‘bitterly disappointed’ after court downplays compensation claim from live export ban
-
General19 hours agoArtificial intelligence could help plan cities, but there are downsides
-
General14 hours agoGetty argues its UK copyright case does not threaten AI